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INTRODUCTION
Primary carcinoma of the fallopian tube (PCFT) accounts 
for about 0.3% to 1.8% of all gynecologic cancers [1]. PCFT is 
a rare tumor compared to ovarian carcinoma [2]. Advanced 
– stage III/IV – fallopian tube cancer is quite difficult to 
distinguish from advanced ovarian cancer (OC). Baekelandt 
et al. [3] in a series of 151 fallopian tube cancer patients, the 
5-year survival was 29% for stage III and 12% for stage IV, 
compared to 73% in stage I. Published data recommend the 
same treatment and follow-up strategy for advanced stage 
of ovarian and fallopian tube cancer, due to their similar 
physiopathology, natural history, clinical characteristics, and 
prognosis. 
The available data on the outcome of early fallopian tube 
cancer limited to one or both tubes (stage IA-IB) is mainly 
made of small sized case series. Early fallopian tube cancer 
is generally managed in the same way as early OC, with the 
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assumption that the prognoses of the two cancers are similar. 
However, comparisons of clinical outcomes of patients with 
fallopian and OC, respectively, have been quite few. A recent 
retrospective case control study demonstrated that, for 
advanced stage PCFT, a similar survival outcome is obtained 
compared to OC patients, whereas the survival was better 
for early stage PCFT compared to OC [4]. Wethington et al. 
[5], in an important retrospective comparison-control study, 
compared the outcome of 55,825 patients suffering from 
PCFT and OC. They found that early and advanced stage PCFT 
have a better overall survival than OC.
However, current studies included patients that were not 
comprehensively staged and did not mention review of the 
pathology with reassessment of pathological grade. It is 
thus likely that stage IIIC patients with nodal spread and/or 
early OCs were included in groups of apparently early stage 
patients [6]. The question of whether or not early fallopian 
tubal cancer has a different outcome compared to early OC 
of similar grade is thus still open. The aim of this study was to 
compare the outcome of carefully studied and staged stage 
IA-IB PCFT to a matched group of OC. 
MATERIALS AND METHODS
1. Study population
Between January 1990 and December 2008, 32 patients 
with stage IA-IB invasive epithelial malignancies of the 
fallopian tube were recorded in the database of three French 
institutions (Claudius Regaud Institute, Toulouse; Gustave 
Roussy Institute, Villejuif; and Oscar Lambret Center, Lille). 
Stringent criteria were used for patient selection. Pathologic 
findings were reviewed by specialized pathologists in 
each center, whenever possible on the original slides. Only 
patients presenting the following criteria were selected: 
1) invasive epithelial fallopian tube carcinoma, 2) serous, 
mucinous, and endometrioid histological subtypes, 3) com-
plete surgery including hysterectomy, bilateral salpingo-
oophorectomy, pelvic and lombo-aortic lymphadenectomy, 
omentectomy, peritoneal washings (multiple random peritoneal 
biopsies and appendectomy were optional); complete surgery, 
by open approach or laparoscopy, completed at the time of 
primary surgery or at the time of surgical reassessment after 
incomplete surgery, 4) stage IA or IB (lymph node negative) 
according to the International Federation of Gynecology and 
Obstetrics (FIGO) criteria established in 1991 after compre-
hensive staging, 5) defined pathological grade according 
to World Health Organization (WHO) classification [7], 6) 
adjuvant chemotherapy had to have been administered at 
least to patients with a stage IA grade 3 (G3), in which case a 
minimum number of three cycles of platinum-based chemo-
therapy was mandatory, and 7) at least one year of follow-up.
Among the 32 potentially eligible patients, 21 were 
excluded for one or several missing criteria. Ten patients 
were incompletely staged, as aortic and pelvic lymph node 
dissection was not performed in seven cases, aortic dissection 
in three additional cases. Four patients were upstaged after 
reassessment (one stage IIA, one stage IIC, two stage IIIC). 
Five patients were excluded after review of pathology: 
undetermined pathological type and original slides not 
available in two patients, endocrine tumor type in one case, 
an intraepithelial tumor in two patients. Grade was not 
described in seven patients (among these patients four were 
also excluded because of incomplete staging, and one patient 
had an intraepithelial tumor). Overall, only 11 patients fulfilled 
the inclusion criteria and made our study group.
2. Control group: ovarian cancer patients
We constituted a group control with 29 patients with OC 
(stage IA-IB), using the same stringent inclusion criteria used 
for PCFT. The initially control group contained 76 patients 
with OC (stage IA-IB). Forty seven patients were excluded for 
one or several missing criteria, of whom 13 were clear cells 
carcinomas. Controls were selected without knowledge of 
patient outcome (Fig. 1). 
 
3. Statistical analysis
Data were summarized by frequency and percentage for 
categorical variables and by median and range for continuous 
variables. To assess differences in clinicopathologic features 
between groups, chi square or Fisher’s exact test was used for 
qualitative variables and the Mann-Whitney test was used for 
continuous variables.
Overall survival and relapse-free survival were calculated 
from the date of the surgery. The first-event definitions were 
death from any cause for overall survival, local regional or 
distant recurrence for relapse-free survival. For overall survival, 
patients alive at the last follow-up news were censored. For 
relapse-free survival, patients alive without disease were cen-
sored at the last follow-up news. Survival rates were estimated 
according to the Kaplan–Meier method and the log rank test 
was used to assess the differences be  tween the groups. All 
statistical tests were two sided, and differences were consi-
dered statistically significant when p<0.05. Statistical analysis 
was done with the Stata ver. 10.0 (Stata Co., College Station, 
TX, USA).Early stage primary carcinoma of fallopian tube
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RESULTS
1. Patients and disease characteristics
Patient’s characteristics are presented in Table 1. The majority 
of patients with PCFT had more delivery (90% with at least 
one delivery) compared to patients with OC (48.1% with one 
or more delivery). Patients with PCFT were more frequently 
treated by previous hormonotherapy (n=4, 44.4%) compared 
to OC patients (n=2, 7.4%, p=0.02). Patients presenting with 
PCFT were older than patients with OC (median, 62 years vs. 
43 years; p<0.01). The histological serous subtype was more 
frequent in the PCFT group (81.8%) than in the OC group 
(17.3%, p<0.01). PCFT were more often grade 2-3 (90.9%) than 
OC (51.7%, p=0.03). Four patients were tested for BRCA1 and/
or BRCA2 (2 in the OC group and 2 other in the PCFT group). 
In those 4 patients, only one of PCFT group was muted and 
the mutation was BRCA2. The methodology applied was full 
Fig. 1. Criteria used for patients’ inclusion. OC: ovarian cancer.
Table 1. Patients and disease characteristic at baseline
Ovaries 
(n=29)
Fallopian tube 
(n=11)
p-value
Age at surgery, 
median (range)
43 (15-60) 62 (55-75) p<0.01
Histological types p<0.01
    Serous 5 (17.2) 9 (81.8)
    Mucinous 15 (51.7) 1 (9.1)
    Endometrioid 9 (31.0) 1 (9.1)
Grade p=0.03
    1 14 (48.3) 1 (9.1)
    2-3 15 (51.7) 10 (90.9)
Values are presented as number (%).Charlotte Vaysse, et al.
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sequencing in all patients. We observed that the trend was 
more pregnancies and status menopausal patients within the 
PCFT group. 
2. Treatment characteristics
Concerning modalities of surgery, all patients had 
complete surgery including hysterectomy, bilateral salpingo-
oophorectomy, pelvic and lombo-aortic lymphadenectomy, 
omentectomy, peritoneal washings (multiple random 
peritoneal biopsies and appendectomy were optional). An 
exception was made for the 6 younger patients to preserve 
fertility. They did not undergo hysterectomy and contralateral 
salpingo-oophorectomy during the first intention surgery. We 
therefore performed laparotomy for 16 patients in the PCFT 
group and 4 patients for the OC group, whereas laparoscopy 
was utilized for 9 patients in the PCFT group and 6 for the 
OC group. Four patients had a laparoscopy converted 
to laparotomy during surgery. For restaging, laparotomy 
was performed in 20 patients in the OC group (100.0%, 
9 unknown) and 5 patients in the PCFT group (50.0%, 1 
unknown), whereas laparoscopy was realized in 5 of the PCFT 
group (50.0%, p<0.01).
Adjuvant chemotherapy following surgical cytoreductive 
effort was respectively administered to 9 (81.8%) and 4 
patients (13.8%) of the PCFT and OC groups, respectively 
(p<0.01). In combination with platinum chemotherapy 
regimen, some patients received paclitaxel (PCFT, 8 cases; OC, 
3 cases), or cyclophosphamide (PCFT, 1 case; OC, 1 case). 
3. Overall survival
The median follow-up was 70.2 months (95% confidence 
interval [CI], 57.1 to 108.4). A total of 4 deaths were observed, 
1 in the PCFT and 3 in the OC group. The five-year overall 
survival was 83.3% (95% CI, 27.3 to 97.5) and 88.0% (95% CI, 
Fig. 2. Overall survival estimated by groups: (A) overall population, (B) grade 2 and grade 3. Relapse-free survival estimated by groups: (C) 
overall population, (D) grade 2 and grade 3. 
PCFT: primary carcinoma of the fallopian tube, OC: ovarian cancer, OS: overall survival, RFS: relapse-free survival.Early stage primary carcinoma of fallopian tube
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66.9 to 96.0) for the PCFT and OC groups, respectively (p=0.93) 
(Fig. 2A).
In the subgroup of patients with grade 2 or 3, risk of death 
was not increased for PCFT compared to OC (p=0.75). The five-
year overall survival was 80% (95% CI, 20.4 to 97.1) and 78.7% 
(95% CI, 47.3 to 92.7) for PCFT and OC (Fig. 2B), respectively.
4. Relapse-free survival
Four patients in each group developed a recurrence. The 
characteristics of those 8 patients are detailed in Table 2. 
Among the patients in the PCFT group with recurrence, 
histological subtypes and grades were: endometrioid/G1 
(n=1), serous/G2 (n=1), serous/G3 (n=2). In the OC group, 3 
patients with recurrence were mucinous/G2 and 1 patient 
was serous/G3. Among eight patients with recurrence, 
four patients have received chemotherapy with platinum, 
two associated with paclitaxel, and two associated with 
cyclophosphamide. Recurrence sites were the pelvic 
peritoneum in four patients (among one peritoneum only), 
lymph nodes in three patients (mesorectum and lombo-
aortic lymph node for one patient, associated with pelvic 
peritoneum for second patient and associated with retro-
vesical mass for the third patient), “peritoneal carcinomatosis 
for one patient,” and atypical site for the last patient (drain 
orifice). 
The treatment of the recurrence was chemotherapy for 
7 patients: three in association with surgery and one with 
surgery and radiation therapy. Because of peritoneal extensive 
disease and no possibility of surgery resection, two patient’s 
received only chemotherapy. For node recurrence just one 
patient was treated by chemotherapy. Only one patients 
recurrence was not specified. A total of 4 deaths were 
observed: 1 in the PCFT and 3 in the OC patient group.
The five-year relapse-free survival was 62.5% (95% CI, 22.9 
to 86.1) and 85% (95% CI, 64.6 to 94.2) in the PCFT and OC 
groups, respectively (p=0.07) (Fig. 2C). In the subgroup of 
patients with grade 2-3, the 5-year relapse-free survival was 
estimated at 57% (95% CI, 17.2 to 83.7) and 72% (95% CI, 41.1 
to 88.6) for PCFT and OC, respectively (p=0.65) (Fig. 2D). 
DISCUSSION
Stage IA-IB PCFT is a very rare entity. It may be even rarer 
than expected considering that the majority of patients 
recorded in our database were excluded after careful review 
of data, suggesting that the available literature may be based 
on biased data. The careful selection process left a small 
number of remaining patients with stage IA-IB fallopian tube 
cancer, with no place for definitive conclusions. However, 
some interesting findings deserve comment. 
There are few case-control studies comparing PCFT to OC. 
Table 2. Characteristics of eight patients who developed a recurrence 
Case
Locali-
zation
Age 
(yr)
Initial 
stage
Histological 
subtype
Tumor 
grade
Adjuvant 
chemotherapy 
(with platinum)
Interval 
(mo)*
Location of the 
recurrence
Treatment 
of 
recurrence
Outcomes
†
1 PCFT 63 IA Serous 3 Paclitaxel 21 Peritoneum CT APD at 38 mo
2 PCFT 62 IA Serous 2 No 31 Pelvic peritoneum, 
node
Surgery+ CT AWD at 70 mo
3 PCFT 75 IA Serous 3 Cyclophos-
phamide
33 Pelvic peritoneum Surgery+ 
CT+RT
Death cancer 
at 56 mo
4 PCFT 67 IA Endo-
metrioid
1 No 68 Node CT AWD at 110 
mo
5 OC 20 IA Mucinous 2 Cyclophos-
phamide
13 Drain orifice  Not 
specified
Death cancer 
at 20 mo
6 OC 31 IA Serous 3 Paclitaxel 52 Pelvic peritoneum Surgery+ CT APD at 57 mo
7 OC 42 IA Mucinous 2 No   6 Peritoneal 
carcinomatosis
CT Death cancer
‡ 
at 20 mo
8 OC 25 IA Mucinous 2 No   7 Retro-vesical masse 
with common 
iliac lymph node 
metastasis 
Surgery+ CT Death other
§ 
at 103 mo
PCFT: primary carcinoma of fallopian tube, CT: chemotherapy, APD: alive with persistent disease, AWD: alive without disease, OC: ovarian 
cancer, RT: radiation therapy. 
*Interval evaluated between date of surgery and recurrence. 
†Interval evaluated between date of surgery and last follow-up news. 
‡Death 
related to cancer. 
§Death related to other cause.Charlotte Vaysse, et al.
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It is important to evaluate OS and progression free survival 
(PFS) to improve the management of PCFT including the early 
stages. Moore et al. [4] compared in a retrospective multi-
institutional case-control study 96 women with serous PCFT 
to 189 patients with OC. The authors found that outcome was 
better for early stage PCFT compared to OC (95% vs. 76%). 
The conclusions are disputable as a result of many potentially 
confounding factors. First, there was a higher proportion of 
stage IA PCFT found incidentally at the surgery for benign 
indications. Second, more PCFT patients were treated with 
adjuvant chemotherapy compared to OC. These PCFT would 
be expected to have a favorable survival. Third, imbalance 
affected the matching process as stage IA was excluded. 
The five-year overall survival was 92% for PCFT patients and 
70% for OC patients (p=0.04). The five-year progression free 
survival curves were not statistically significant at 62% and 
50%, respectively (p=0.09) [4]. The analysis that all initially 
included stage of fallopian tube cancer was not complete 
because of the exclusion of early stage IA in this cohort. 
Another recent large retrospective study compared the 
clinical characteristics and outcomes for PCFT and OC (all 
stages confounded) retrieved from epidemiological databases 
[5]. The authors concluded that survival was similar for 
early stage (I and II) PCFT and OC (p=0.19). Although their 
study included a large number of patients, several flaws 
may be suggested. The databases lacked information on 
adjuvant therapy and cytoreductive status, on the quality of 
pathology review, and on the comprehensiveness of staging. 
Considering the high rejection rate in our study, it is likely that 
some non invasive tumors were included as invasive, and that 
a proportion of patients were actually stage IIIC in this paper 
and in other papers of the literature as well [5]. Our study is 
the only available one using strict inclusion criteria. Our results 
are also in accordance with the series of Baekelandt et al. [3], 
who found 73% OS and 61% PFS in stage I PCFT. In addition, 
the authors analysed prognostic factors of stage I PCFT 
and retained the depth of infiltration and tumor rupture in 
multivariate analysis. These factors seem to be different from 
prognosis factors of early ovarian carcinomas, in opposition 
to similarities in characteristics and prognosis between more 
advanced stage disease of tubal and ovarian carcinomas 
[3]. When comparing patients with similar grades, overall 
survival outcomes are similar between fallopian tube and OCs. 
However, there is a trend toward a decrease of relapse free 
survival in the PCFT group, even if the power of the study is 
too weak to reach statistical significance (p=0.07). This finding 
seems to be depend only on the higher proportion of high 
grade tumors in the PCFT group. Actually, stage IA grade 1 
(G1) fallopian tube cancer is an extremely rare disease in our 
experience.
Moreover, it is important to know if the therapeutic care of 
PCFT should be duplicate to OC. In fact, the management of 
PCFT is usually similar to OC. First, complete cytoreductive 
surgery is the treatment of choice for PCFT [8]. As all patients 
were stage I, with no associated endometriosis, none of them 
underwent an anterior resection surgery. Deffieux et al. [6] 
reported in their study of 19 patients that 29% of stage I PCFT 
had positive lymph nodes. This finding stresses the need for a 
complete lymph node dissection including all pelvic and para-
aortic chains up to the level of the left renal vein. Previous 
studies suggested early lymphatic spread of PCFT, even in 
apparent early stages [3,9-11]. The role of laparoscopic surgery 
is still controversial. In our study, we performed a laparotomy 
in the majority of cases in the PCFT and OC groups. Palpation 
is impossible during laparoscopy which offers a chance 
to detect small tumor in the porta hepatis, hepatophrenic 
junction, or omentum. For this reason, the possibility of biased 
patient inclusion or exclusion might occur in terms of tumor 
distribution. However, the actual trend according to Leblanc 
et al. [12], laparoscopy seems to be an acceptable technical 
option to performing restaging of apparently early adnexal 
carcinomas. Some areas - the posterior aspect of the liver, 
high part of left hemidiaphragm - are difficult to explore, but 
the likelihood of finding isolated implants in these areas is 
low. 
In terms of adjuvant therapy, the PCFT is generally managed 
as OC. Several reports have found that patients who received 
platinum based chemotherapy responded well to these treat-
ments [5,13-17]. Recently, in a larger study, Pectasides et al. 
[18] suggested the combination of carboplatin plus paclitaxel 
as the standard chemotherapy regimen for PCFT patients. In 
our clinical practice, intravenous adjuvant chemo  therapy with 
platinum is recommended after complete surgical staging, 
for patients with stage IC or stage IA or IB, grade 3. Stage IA 
or IB grade 2 (G2) patients are proposed che  mo  therapy after 
multidisciplinary discussion and thorough patient information. 
For IA or IB grade 1 “patients” “no” adju  vant treatment after 
the surgery is suggested (www.sor-cancer.fr). 
In addition, recent studies indicate that a proportion of these 
tumors (ovarian, tubal or peritoneal) arise from the distal 
fallopian tube. High grade PCFT and high grade OC may be 
the same disease. Previously, pathology analyses to distinguish 
between fallopian and ovarian tumors, even with advanced 
tumors, is often problematic. The shared immunophenotype 
suggests a common cell of origin in all categories, irrespective 
of site [19]. Jarboe et al. [20] suggested a two-pathway 
concept of ovarian carcinogenesis, underscoring molecular 
differences between low-grade and high-grade serous Early stage primary carcinoma of fallopian tube
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tumors of the ovary. The former initiates in the ovarian surface 
epithelium, mullerian inclusions, or endometriosis in the 
ovary. The latter arises from the endosalpinx and encompasses 
a subset of serous carcinomas. Criteria for distinguishing 
ovarian, tubal, and primary peritoneal serous carcinomas are 
tumor distribution and presence or absence of a precursor 
condition [21]. Prophylactic salpingo-oophorectomy in 
women with mutations in BRCA1 or BRCA2 has revealed that 
many early cancers in these women arise in the fallopian 
tube, specially the distal portion (fibrium). Recent studies 
that carefully examined the fallopian tubes suggest a high 
frequency of early ovarian or peritoneal serous carcinoma 
in patients (BRCA+ or BRCA-), meaning that some of these 
tumors have a fimbrial or tubal origin [19,21-23]. All our 
patient were BRCA 1-2 negative, and as there was no apparent 
pathology of the fallopian tube, one to two sections per tube 
was performed according to standard recommendations [24]. 
Therefore the fimbria was not exhaustively investigated [24].
Our study has several limitations. It is retrospective by 
nature, including patients managed before the paclitaxel era. 
The number of patients is quite small as a result of the drastic 
inclusion criteria. We have excluded many patients because 
of the lack of standardization of surgical practices and the 
impossibility to confirm histological type and grade of tumors 
at the time of slide review. We recognize the imbalance of the 
histological types in the PCFT and OC groups, and the unusual 
repartition of these histological tumors [25]. We have elected 
to accept a small but carefully defined group rather than a 
larger but heterogeneous one. Even though OC patients were 
matched on the basis of stage, grades were significantly lower 
in the OC group. Platinum based chemotherapy was given to 
9 (81.8%) and 4 patients (13.8%) of the PCFT and OC patients, 
respectively, as a consequence of the higher occurrence of 
grade 2-3 in the study group. However, when grade and 
consequent adjuvant chemotherapy was taken into account, 
there does not seem to be any difference in outcome 
between the PCFT and OC groups. 
However, given the rarity of these tumors, it is the first study 
which compare with drastic criteria inclusion outcomes for 
early stage (IA-IB) PCFT and OC in a matched, case–control 
comparison of selected cases. More patients were treated 
by chemotherapy in the PCFT group than in the OC group 
because of a higher proportion of grade 3 patients in the PCFT 
group, making it impossible to confirm that PCFT has a similar 
overall survival to OC. The surgical and adjuvant therapy 
management of fallopian tube carcinomas should mirror that 
Table 3. Review of the literature on fallopian tube carcinoma: principal reports
Reference No. of case Study design Conclusion
Baekelandt et al. [3] 
2000 
151 Retrospective study  Stage I: OS (73%) and PFS (61%), Stage III: 29%, Stage IV: 12%
Early stage: PCFT seem to differ from those in patients with OC.
Advanced stage: Published data recommend the same treatment and follow-up 
strategy for ovarian and fallopian tube cancer.
Moore et al. [4] 
2007
PCFT: 96
OC: 189
Retrospective multi-
institutional case-
control study
Advanced stage: PCFT, a similar survival outcome is obtained compared to OC 
patients. 3-yr OS: PCFT and OC 59%. 
Early stage 5-yr OS: PCFT > OC, PCFT 95% and OC 76% (p=0.02). 
Wethington et al. 
[5] 2008
PCFT: 1,576
OC: 54,249
Retrospective multi-
institutional case-
control study
PCFT present earlier and at advanced stage have a better OS than OC.
For stage III 5-yr survival: PCFT 54% compared with 30% OC
Deffieux et al. [6] 
2005 
19 Retrospective study  The frequency of lymph node metastases according to the stage of the disease (stage 
I, II and III) was 29, 50%, and 60% respectively. A complete lymphadenectomy 
(pelvic and para-aortic chains ) should be performed in patients with primary 
tubal carcinoma, even in patients with stage I disease.
Pectasides et al. [18] 
2009 
64 Retrospective multi-
institutional case-
control study
The median time to tumor progression was not reached in patients with stage I/II 
and was 38 mo for patients with stage III/IV (p=0.004).
Optimally cytoreduced patients with PFTC treated with platinum and paclitaxel-
based chemotherapy regimen have an excellent possibility of survival.
Roh et al. [19]  
2009
SC: 87
EC: 37
Retrospective study  New theory: proportion of these tumors (ovarian, tubal or peritoneal) arise from the 
distal fallopian tube.
Jarboe et al. [20] 
2008
Review of the 
literature
Two-pathway concept of ovarian carcinogenesis, underscoring molecular differences 
between low-grade and high-grade serous tumors of the ovary.
Semmel et al. [24] 
2009
Case report and 
review
The distal fallopian tube seems to be the principal site of early serous cancer in 
women with a hereditary risk for OC.
OS: overall survival, PFS: progression-free survival, PCFT: primary carcinoma of the fallopian tube, OC: ovarian cancer, SC: serous carcinomas, EC: 
endometrioid carcinomas, RFS: relapse-free survival.Charlotte Vaysse, et al.
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of OC (Table 3). 
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Standards for Different Types of Articles
Guidelines for six different types of articles have been adopted by the Journal of Gynecologic Oncology:
1. CONSORT (Consolidated Standards of Reporting Trials) standards for reporting randomized trials
2. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) guidelines for 
reporting systematic reviews and meta-analyses
3. MOOSE (Meta-analysis of Observational Studies in Epidemiology) guidelines for meta-analyses 
and systematic reviews of observational studies
4. STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines for 
the reporting of observational studies
5. STARD (Standards for Reporting of Diagnostic Accuracy) standards for reporting studies of 
diagnostic accuracy
6. REMARK (Reporting of Tumor Markers Studies) guidelines for reporting tumor marker prognostic 
studies
  Investigators who are planning, conducting, or reporting randomized trials, meta-analyses 
of randomized trials, meta-analyses of observational studies, observational studies, studies of 
diagnostic accuracy, or tumor marker prognostic studies should be familiar with these sets of 
standards and follow these guidelines in articles submitted for publication.
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